HeartBeam (NASDAQ:BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai aimed at accelerating the development and clinical validation of next-generation artificial intelligence ECG algorithms.
The partnership will combine HeartBeam’s patented ECG platform—which captures the heart’s electrical activity from three non-coplanar dimensions—with Mount Sinai’s clinical and artificial intelligence expertise to build advanced diagnostic tools.
According to the company, “Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform.”
The collaboration will involve several prominent cardiovascular and AI researchers from Mount Sinai. Joshua Lampert, MD, FACC—known for his work in AI-enabled cardiology and cardiovascular deep learning—will participate alongside Vivek Reddy, MD, a leading electrophysiologist and cardiac innovator. Girish N. Nadkarni, MD, MPH, Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will also help guide the scientific and clinical direction of the project.
HeartBeam said the joint effort is designed to enhance the diagnostic capabilities of its ECG platform and support the development of AI-driven tools that could improve the detection and monitoring of cardiac conditions.
More about HeartBeam
HeartBeam, Inc. is a medical technology company focused on advancing the detection and monitoring of serious cardiac conditions. The company is developing what it describes as the first cable-free device capable of collecting ECG signals in three non-coplanar directions and converting those signals into a synthesized 12-lead ECG.
The platform is intended for portable use, allowing patients to capture ECG data outside of traditional medical settings and enabling physicians to remotely monitor heart health, identify trends and detect acute cardiac events.
HeartBeam’s 3D ECG technology received U.S. Food and Drug Administration clearance for arrhythmia assessment in December 2024, followed by FDA clearance for its 12-lead ECG synthesis software in December 2025. The company holds more than 20 issued patents related to its technology platform.